AP Biosciences 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
efdamrofusp alfa (IBI-302) / Innovent Biologics
NCT05972473: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects with NAMD

Active, not recruiting
3
600
RoW
Aflibercept Ophthalmic, IBI302
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration
02/27
04/27
NCT04820452: A Study of IBI302 in Patients With nAMD

Completed
2
231
RoW
Low dose IBI302, High dose IBI302, Aflibercept
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration
01/23
01/23
NCT05403749: A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Completed
2
132
RoW
dose 1 IBI302, Aflibercept, dose 2 IBI302
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration
05/24
05/24
NCT06908876: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)

Recruiting
2
150
RoW
IBI302, Faricimab
Innovent Biologics Technology Limited (Shanghai R&D Center)
Diabetic Macular Oedema
12/26
02/27
NCT05961007: Evaluation of IBI302 Injection in nAMD or DME

Suspended
1/2
234
RoW
Intravitreal injection of IBI302(dose 1), Intravitreal injection of IBI302(dose 2), Intravitreal injection of IBI302(dose 3), Intravitreal injection of Aflibercept
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
10/23
04/24
ChiCTR2100049055: A multicenter, randomized controlled trial of advanced age-related macular degeneration

Not yet recruiting
N/A
40
 
IBI302 treatment ;Treatment of EYLEA
Shanghai General Hospital; Shanghai General Hospital, project funding
age-related macular degeneration
 
 
AP203 / AP Biosciences
APT-CUBE, NCT05473156: A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Recruiting
1/2
168
RoW
AP203
AP Biosciences Inc.
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
12/26
12/27
NCT06020001: Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

Completed
N/A
60
Europe
AP203 mixture (RESCOVIN®), Placebo
AronPharma Sp. z o. o.
Upper Respiratory Tract Infection Bacterial
04/23
04/23
AP505 / AP Biosciences
NCT06724263: A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Not yet recruiting
2
120
RoW
B1962, B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
Tasly Biopharmaceuticals Co., Ltd., Shanghai East Hospital
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer, Hepatocellular Carcinoma (HCC), Colorectal Cancer, Non-Squamous Non-Small Cell Lung Cancer
08/26
08/26
NCT06838546: A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer

Not yet recruiting
2
80
RoW
B1962, B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
Tasly Biopharmaceuticals Co., Ltd., Sir Run Run Shaw Hospital
Advanced Colorectal Cancer
01/27
01/27
NCT06723964: A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

Active, not recruiting
1
35
RoW
AP505
AP Biosciences Inc.
Advanced Solid Tumors
10/24
11/25
NCT05650385: A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Not yet recruiting
1
68
RoW
B1962
Tasly Biopharmaceuticals Co., Ltd.
Neoplasms Malignant
12/23
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
efdamrofusp alfa (IBI-302) / Innovent Biologics
NCT05972473: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects with NAMD

Active, not recruiting
3
600
RoW
Aflibercept Ophthalmic, IBI302
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration
02/27
04/27
NCT04820452: A Study of IBI302 in Patients With nAMD

Completed
2
231
RoW
Low dose IBI302, High dose IBI302, Aflibercept
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration
01/23
01/23
NCT05403749: A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Completed
2
132
RoW
dose 1 IBI302, Aflibercept, dose 2 IBI302
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration
05/24
05/24
NCT06908876: A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)

Recruiting
2
150
RoW
IBI302, Faricimab
Innovent Biologics Technology Limited (Shanghai R&D Center)
Diabetic Macular Oedema
12/26
02/27
NCT05961007: Evaluation of IBI302 Injection in nAMD or DME

Suspended
1/2
234
RoW
Intravitreal injection of IBI302(dose 1), Intravitreal injection of IBI302(dose 2), Intravitreal injection of IBI302(dose 3), Intravitreal injection of Aflibercept
Innovent Biologics (Suzhou) Co. Ltd.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
10/23
04/24
ChiCTR2100049055: A multicenter, randomized controlled trial of advanced age-related macular degeneration

Not yet recruiting
N/A
40
 
IBI302 treatment ;Treatment of EYLEA
Shanghai General Hospital; Shanghai General Hospital, project funding
age-related macular degeneration
 
 
AP203 / AP Biosciences
APT-CUBE, NCT05473156: A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies

Recruiting
1/2
168
RoW
AP203
AP Biosciences Inc.
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
12/26
12/27
NCT06020001: Clinical Evaluation of the AP203 Plant Extract Mixture in Adult Patients With Increased Incidence of Viral and/or Bacterial Upper Respiratory Tract Infections

Completed
N/A
60
Europe
AP203 mixture (RESCOVIN®), Placebo
AronPharma Sp. z o. o.
Upper Respiratory Tract Infection Bacterial
04/23
04/23
AP505 / AP Biosciences
NCT06724263: A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Not yet recruiting
2
120
RoW
B1962, B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
Tasly Biopharmaceuticals Co., Ltd., Shanghai East Hospital
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer, Hepatocellular Carcinoma (HCC), Colorectal Cancer, Non-Squamous Non-Small Cell Lung Cancer
08/26
08/26
NCT06838546: A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal Cancer

Not yet recruiting
2
80
RoW
B1962, B1962 is a PD-L1/VEGF bispecific antibody fusion protein.
Tasly Biopharmaceuticals Co., Ltd., Sir Run Run Shaw Hospital
Advanced Colorectal Cancer
01/27
01/27
NCT06723964: A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors

Active, not recruiting
1
35
RoW
AP505
AP Biosciences Inc.
Advanced Solid Tumors
10/24
11/25
NCT05650385: A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors

Not yet recruiting
1
68
RoW
B1962
Tasly Biopharmaceuticals Co., Ltd.
Neoplasms Malignant
12/23
10/25

Download Options